Clinical Trial Update: Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia [Phase 1]

View source ↗

Summary

Phase 1 safety study evaluating HspE7 in combination with Poly-ICLC in patients with cervical intraepithelial neoplasia (CIN).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Intraepithelial Neoplasia

Drugs mentioned

• HspE7 (Heat shock protein 70–E7 fusion protein)
• Poly-ICLC (poly-ICLC)

Snippet

Sponsor: Nventa Biopharmaceuticals Corporation | Conditions: Cervical Intraepithelial Neoplasia | Phase 1 | Status: UNKNOWN